- Conditions
- Schizophrenia
- Interventions
- Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 937 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 39
- States / cities
- Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole IM Depot, Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 43
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 32 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- GA Depot, Placebo
- Drug · Other
- Lead sponsor
- Mapi Pharma Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Pasadena, California + 8 more
- Conditions
- Bipolar I Disorder
- Interventions
- Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more
- Conditions
- HIV, AIDS, Opioid Dependence, Drug Dependence
- Interventions
- Extended-Release Naltrexone
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 3
- States / cities
- Hartford, Connecticut • New Haven, Connecticut • Springfield, Massachusetts
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole depot, Placebo depot
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 843 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Anaheim, California • National City, California + 39 more
- Conditions
- Opioid Use Disorder
- Interventions
- Buprenorphine, buprenorphine and naloxone, hydromorphone, placebo
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas